215 related articles for article (PubMed ID: 33675866)
1. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG
Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866
[TBL] [Abstract][Full Text] [Related]
2. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
4. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
5. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
6. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
[TBL] [Abstract][Full Text] [Related]
7. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
8. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.
Carrere N; Vernejoul F; Souque A; Asnacios A; Vaysse N; Pradayrol L; Susini C; Buscail L; Cordelier P
Hum Gene Ther; 2005 Oct; 16(10):1175-93. PubMed ID: 16218779
[TBL] [Abstract][Full Text] [Related]
10. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
13. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
14. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J
Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488
[TBL] [Abstract][Full Text] [Related]
15. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
Reubi JC; Schonbrunn A
Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
[TBL] [Abstract][Full Text] [Related]
16. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
Körner M; Waser B; Reubi JC
Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
[TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
20. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]